Clinical Trials Directory

Trials / Completed

CompletedNCT04379297

COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE)

Status
Completed
Phase
Study type
Observational
Enrollment
1,870 (actual)
Sponsor
Luxembourg Institute of Health · Other Government
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

CON-VINCE (COvid-19 National survey for assessing VIral spread by Non-affected CarriErs) is a national, monocentric, and longitudinal study aiming to evaluate the spread dynamics of the COVID-19 disease within the Luxembourgish population. Participants who are clinically asymptomatic or present with only mild symptoms will be followed up longitudinally, regularly tested for SARS-CoV-2 by RT-PCR, antibody status, and subjected to an epidemiological, clinical and biological phenotyping to better understand the nature, dynamics of infectivity and spread of the virus in the population. CON-VINCE will also track the psychological and socio-economic impact of long-term containment measures on the general population.

Detailed description

To capture the dynamics and impact of the virus spread in the Luxembourgish population, data and sample collection is done every two weeks for two months (4 times in total) with a final follow-up one year after the participant's inclusion in the study. Participants complete questionnaires before each sample collection. The baseline questionnaire captures demographic data, medical history, behavioral and psychological data, and socio-economic status. Participants provided information on medical history, history of allergies, smoking, and chronic medication taken regularly. COVID-19-related data and environmental conditions of the household were obtained.

Conditions

Timeline

Start date
2020-04-10
Primary completion
2021-06-10
Completion
2022-09-30
First posted
2020-05-07
Last updated
2024-08-14

Locations

1 site across 1 country: Luxembourg

Source: ClinicalTrials.gov record NCT04379297. Inclusion in this directory is not an endorsement.